CRISPitope: A generic platform to model target antigens for adoptive T cell transfer therapy in mouse tumor models

STAR Protoc. 2022 Jan 7;3(1):101038. doi: 10.1016/j.xpro.2021.101038. eCollection 2022 Mar 18.


This protocol details the procedure for CRISPR-assisted insertion of epitopes (CRISPitope), a flexible approach for generating tumor cells expressing model CD8+ T cell epitopes fused to endogenously encoded gene products of choice. CRISPitope-engineered tumor cells can be recognized by T cell receptor-transgenic (TCRtg) CD8+ T cells that are widely used in immunology research. Using mice inoculated with CRISPitope-engineered tumor cells, researchers can investigate how the choice of the target antigen for T cell immunotherapies influences treatment efficacy and resistance mechanisms. For complete details on the use and execution of this protocol, please refer to Effern et al. (2020).

Keywords: Biotechnology and bioengineering; CRISPR; Cancer; Cell Biology; Flow Cytometry/Mass Cytometry; Immunology; Model Organisms; Molecular Biology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes*
  • Disease Models, Animal
  • Epitopes, T-Lymphocyte
  • Immunotherapy, Adoptive / methods
  • Mice
  • Neoplasms* / therapy
  • Receptors, Antigen, T-Cell / genetics


  • Epitopes, T-Lymphocyte
  • Receptors, Antigen, T-Cell